MyMD has assembled a compelling portfolio of drug candidates to regulate the immunometabolic response through well-defined and efficient clinical pathways. We are using pre-clinical and clinical longevity research and studies to explore the development of drug products that target aging and age-related diseases, and alleviate chronic pain, anxiety, and sleep disorders.
MyMD is using pre-clinical and clinical longevity research and studies to explore the development of drug products that target aging and age-related diseases, and alleviate chronic pain, anxiety and sleep disorders.
MYMD-1® is an orally available, next-generation TNF-alpha inhibitor with potential to provide meaningful therapeutic solutions to patients not served by current TNF-alpha inhibitors. Taken orally, it is easier to administer and possesses a better safety profile than currently approved anti-TNF therapies. Capable of crossing the blood brain barrier, MYMD-1® holds promise in treating CNS-based autoimmune and inflammatory diseases such as multiple sclerosis. It has also demonstrated its potential to slow the aging process and extend healthy lifespan.
Learn MoreSupera-CBD is a synthetic, non-toxic cannabidiol (CBD) analog that is a more potent CB2 agonist than plant-based CBD. In addition to its potential role in managing addiction, anxiety, chronic pain and seizures, Supera-CBD has also been shown to have anti-inflammatory effects. Supera-CBD is being developed to address anxiety, chronic pain, and seizures and is expected to begin human trials as a therapy for epilepsy, followed by chronic pain.
Learn MoreWe’re partnering with Internationally renowned scientists and academics to validate the promise of our drug candidates as anti-inflammatory and anti-ageing technologies that treat the causes of disease and decline rather than simply focusing on the symptoms. MyMD is working to rapidly advance MYMD-1® and Supera-CBD in clinical trials while identifying and validating additional novel targets.
See the Research